Table 1 Study characteristics
From: Evaluating dose response from flexible dose clinical trials
Study A N* = 234 | Study B N* = 172 | |
|---|---|---|
Disease state | Bipolar I mania | Schizophrenia |
Duration of study | 12 weeks | 28 weeks |
Visit intervals | 2 weeks | 2–4 weeks |
Dosages, mg/day | Olanzapine (5, 10, 15, 20) | Olanzapine (10, 15, 20) |
Starting dose, mg/day | Olanzapine (15) | Olanzapine (15) |
Gender, % female | 60.2 | 35.1 |
Age in years, mean (SD) | 39.9 (13.2) | 36.2 (10.7) |
Symptom severity, mean (SD) | YMRS total, 30.7 (7.5) | PANSS total, 96 (16.6) |